课题基金 / 基金详情

The Genetic and Molecular Basis of Cholesterol Efflux

The Genetic and Molecular Basis of Cholesterol Efflux
胆固醇流出的遗传和分子基础
批准号:
10307083
负责人:
Anand Kumar Rohatgi
金额:
$69.66万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-12-15 至 2024-11-30

项目摘要

项目成果

Anand Kumar Rohatgi的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
Project Summary Low high-density lipoprotein cholesterol (HDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of death. However, strategies to improve atheroprotection by raising HDL-C levels have failed to improve outcomes. Macrophage- specific cholesterol efflux is the first critical step of reverse cholesterol transport, a key atheroprotective pathway. Cholesterol efflux is inversely associated with incident ASCVD events; however, the mechanisms that underlie variation in cholesterol efflux are unknown. There is a critical need to identify factors that regulate cholesterol efflux to advance understanding of the reverse cholesterol transport pathway, a biological process that has broad implications across a variety of disease states including atherosclerosis. The overall objective of this proposal is to systematically ascertain the genetic and molecular factors governing variation in cholesterol efflux. We propose to carry out our objective by using two large, population- based multi-ethnic cohorts, the Dallas Heart Study (DHS) and the Multi-Ethnic Study of Atherosclerosis (MESA) to pursue the following aims: 1) determine the contribution of genetic factors to inter-individual variability in cholesterol efflux and whether these factors are causally associated with ASCVD; and 2) identify the metabolite and protein signature of cholesterol efflux in a sex- and ethnicity-specific manner. We expect to characterize the genetic, metabolic, and protein regulators of cholesterol efflux to support future studies targeting manipulation of the reverse cholesterol transport pathway.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.jacl.2022.06.010
发表时间: 2022-07
期刊: Journal of clinical lipidology
影响因子: 4.4
作者: [R. Mackey;Anand Rohatgi]
通讯作者: R. Mackey;Anand Rohatgi
DOI: 10.1161/circulationaha.120.044221
发表时间: 2021-06-08
期刊: Circulation
影响因子: 37.8
作者: [Rohatgi A, Westerterp M, von Eckardstein A, Remaley A, Rye KA]
通讯作者: Rye KA
Higher High-Density Lipoprotein Cholesterol-Good Omen, Bad Omen, or Not an Omen at All.
高密度脂蛋白胆固醇升高——好兆头、坏兆头或根本不是兆头。
DOI: 10.1001/jamacardio.2022.5143
发表时间: 2023
期刊: JAMA cardiology
影响因子: 24
作者: [Wilkins,John, Rohatgi,Anand]
通讯作者: Rohatgi,Anand
DOI: 10.3390/ijms242115526
发表时间: 2023-10-24
期刊: International journal of molecular sciences
影响因子: 5.6
作者: []
通讯作者:
共 13 条
    Lipoprotein Metabolism and Excess Cardiometabolic Risk in South Asians
    • 批准号:
      10705254
    • 项目类别:
    • 资助金额:
      $66.49万
    • 财政年份:
      2022
    • 负责人:
      Anand Kumar Rohatgi
    • 依托单位:
    Lipoprotein Metabolism and Excess Cardiometabolic Risk in South Asians
    • 批准号:
      10539768
    • 项目类别:
    • 资助金额:
      $66.57万
    • 财政年份:
      2022
    • 负责人:
      Anand Kumar Rohatgi
    • 依托单位:
    Mentoring Patient-Oriented Research in Deep Lipid Phenotyping for Cardiovascular Disease
    • 批准号:
      9903436
    • 项目类别:
    • 资助金额:
      $11.59万
    • 财政年份:
      2019
    • 负责人:
      Anand Kumar Rohatgi
    • 依托单位:
    Mentoring Patient-Oriented Research in Deep Lipid Phenotyping for Cardiovascular Disease
    • 批准号:
      10613478
    • 项目类别:
    • 资助金额:
      $11.43万
    • 财政年份:
      2019
    • 负责人:
      Anand Kumar Rohatgi
    • 依托单位:
    海外基金